This CME/CE activity is derived from content presented at the 6th Annual Advanced Curriculum for Multiple Sclerosis 2021 Virtual CME/CE Course. The expert faculty, led by Dr. Fred D. Lublin, will first review the science of the evolving spectrum of multiple sclerosis (MS) to better understand the course of MS disease activity, as well as optimal treatment solutions to reduce relapses, minimize the occurrence of brain lesions, and delay disability progression. Next, an analysis of the latest therapeutic advances in MS science, including oral fumarate therapies, for the efficacy, safety, and GI tolerability of newly approved therapies to treat patients with multiple sclerosis will be discussed. Lastly, the faculty will delve into the development patient-focused treatment strategies, utilizing the MS comprehensive care team to overcome barriers to treatment. The faculty will conclude with an interactive expert panel discussion, where the application of new science regarding patient-focused treatment strategies across the spectrum of MS will be discussed.
Neurologists, MS specialists, nurse practitioners, physicians’ assistants, nurses, and pharmacists who comprise the comprehensive MS care team, as well as other healthcare professionals involved in the management of patients with multiple sclerosis
- Review the science of the evolving spectrum of MS to better understand the course of MS disease activity, as well as the best treatment solutions to reduce relapses, less the occurrence of brain lesions, and delay disability progression.
- Analyze the latest therapeutic advances in MS science, including oral fumarate therapies, for the efficacy, safety, and GI tolerability of newly approved therapies to treat patients with MS.
- Develop patient-focused treatment strategies utilizing the MS comprehensive care team to overcome barriers to treatment in all patients with MS.
I. The Principles of Patient-Focused Clinical Decision-Making to Slow Disease Progression and Maintain Cognition – Clyde Markowitz, MD
II. A Clinical Trial Analysis of the Efficacy, Safety, and Tolerability Data for Fumarates, CD20 and S1P Therapeutics – Patricia Coyle, MD
III. Identifying and Reducing Barriers to Treatment with the MS Comprehensive Care Team – June Halper, MSN, APN-C, MSCN
IV. Interactive Panel Discussion – Fred D. Lublin, MD and Expert Faculty
Disclosures of Conflict of Interest
It is the policy of AcademicCME that all faculty, instructors, and planners disclose real or apparent conflicts of interest relating to the topics of this educational activity.
The faculty reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CE activity:
|Faculty||Relationship Identified With:|
Fred D. Lublin, MD
|Consultant/Advisor: Acorda Therapeutics; Actelion Pharmaceuticals Ltd; Apitope; Atara Biotherapeutics, Inc.; Avotres Inc.; Biogen; BrainStorm Cell Limited; Celgene Corporation; EMD Serono, Inc.; F. Hoffmann-La Roche Ltd; Genentech, Inc.; Greenwich Biosciences, a GW Pharmaceuticals PLC Company; Immunic Therapeutics; Innate Immunotherapeutics; Janssen Global Services, LLC; Jazz Pharmaceuticals, Inc.; Mapi-Pharma Ltd.; MedDay Pharmaceuticals; MedImmune Pharma; Mylan; Novartis AG; Orion Biotechnology; Polpharma; Population Council; Receptos; Sanofi Genzyme; Teva Pharmaceutical Industries Ltd.; TG Therapeutics, Inc.; Viela Bio
Grant/Research Support: Actelion Pharmaceuticals Ltd; Biogen; BrainStorm Cell Limited; Novartis AG; Sanofi Genzyme
Speaker’s Bureau: Sanofi Genzyme
Patricia Coyle, MD
|Consultant/Advisor: Accordant, A CVS Caremark Company; Biogen; Bristol-Myers Squibb; Celgene Corporation; F. Hoffmann-La Roche Ltd; Genentech, Inc.; GlaxoSmithKline plc; Janssen Global Services, LLC; Novartis AG; Sanofi Genzyme; Viela Bio
Grant/Research Support: Actelion Pharmaceuticals Ltd; Alkermes; Corrona, LLC; F. Hoffmann-La Roche Ltd; Genentech, Inc.; MedDay Pharmaceuticals; Novartis AG
June Halper, MSN, APN-C, MSCN
|Nothing to disclose|
Clyde Markowitz, MD
|Consultant/Advisor: Actelion Pharmaceuticals Ltd; Biogen; Bayer AG; Celgene Corporation; EMD Serono, Inc.; F. Hoffmann-La Roche Ltd; Genentech, Inc.; Novartis AG; Sanofi Genzyme; Teva Pharmaceutical Industries Ltd.|
Planners and Peer Reviewers
Timothy Hayes, MD, PhD; Kim Cheramie, MSN, RN-BC; John Fanikos, RPh; Amy Perrin Ross, APN, MSN, CNRN, MSCN; Nicole McMenamin and Chelsey Benedek hereby state that they or their spouse/life partner do not have any financial relationships to products or devices with any commercial interests related to the content of this activity of any amount during the past 12 months.
In support of improving patient care, AcademicCME is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.
Credit Designation Statements
AcademicCME designates this enduring material for a maximum of 1.0 AMA PRA Category 1 CreditTM.
AcademicCME designates this enduring material for a maximum of 1.0 CNE Contact Hour.
AcademicCME designates this continuing education activity for 1.0 CPE Contact Hour (0.10 CEU) of continuing pharmacy education credit (JA4008190-0000-21-008-H04-P).
Clinicians should claim only the credit commensurate with the extent of their participation in the activity.
This activity has been supported by an independent educational grant from Biogen
Disclosure of Unlabeled Use
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. AcademicCME and Biogen do not recommend the use of any agent outside of the labeled indications.
Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications on dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.
Method of Participation
In order to claim credit, participants must complete the following:
- Read the learning objectives, accreditation information and faculty disclosures at the beginning of this activity.
- Complete the Pre-Activity Questions
- Read or Review the activity content.
- Complete the Post-Activity Test Questions and Evaluation.
- Learners who receive a grade of 70% or better on the Post-Activity Test Questions and complete the Evaluation will receive appropriate credit as indicated (CME, CNE, and/or CPE credit).
- CPE credit will be posted to the learner’s CPE Monitor profile within 60 days of completion.
- CME and CNE credit will be issued appropriate certificate of completion.
- Others may request a “certificate of completion”.
- Learners should claim only the credit commensurate with the extent of their participation in the activity.
CE Inquiries/Special Needs
For all CE inquiries or special needs, please contact [email protected].